Paclitaxel CAS#33069-62-4

  • Precision Microtubule Binding: Selectively associates with polymerized microtubules to drive structural stabilization while effectively disrupting normal cellular division.

  • Proven Antineoplastic Efficacy: Demonstrates established therapeutic success against diverse malignancies, including ovarian, breast, non-small cell lung, and colorectal cancers.

  • Mitotic Cell Cycle Arrest: Triggers targeted cell cycle arrest specifically at the mitotic phase, halting the proliferation and growth of tumor cells.

  • Established Clinical Utility: Extensively integrated into advanced oncological treatment protocols, backed by robust efficacy proven across Phase II and Phase III clinical trials.

WhatsApp
Product Details

Derived as a diterpenoid monomer extracted from the bark of Taxus species, paclitaxel functions as a structurally complex secondary metabolite representing the sole known therapeutic agent capable of concurrently driving microtubule polymerization and stabilizing the resulting polymeric structures. Furthermore, isotopic labeling investigations confirm that paclitaxel selectively associates with polymerized microtubules while exhibiting no affinity for unpolymerized free tubulin dimers.

Paclitaxel CAS#33069-62-4Cellular exposure to paclitaxel triggers substantial intracellular accumulation of microtubules, which critically impairs diverse physiological cellular processes—most notably halting cell cycle progression during the mitotic phase to successfully inhibit standard cell division. Furthermore, comprehensive Phase II and Phase III clinical evaluations have confirmed its primary therapeutic efficacy in treating ovarian and breast carcinomas, while also displaying verified antineoplastic activity across an array of other malignancies, including non-small cell lung cancer, colorectal carcinoma, melanoma, head and neck malignancies, lymphomas, and gliomas.

Paclitaxel CAS#33069-62-4

Parameters

Melting point 213 °C (dec.)(lit.)
alpha D20 -49° (methanol)
Boiling point 774.66°C (rough estimate)
density 0.2
refractive index -49 ° (C=1, MeOH)
Fp 9℃
storage temp. 2-8°C
solubility methanol: 50 mg/mL, clear, colorless
form powder
pka11.90±0.20(Predicted)
color white
Water Solubility 0.3mg/L(37 ºC)
λmax227nm(MeOH)(lit.)
Merck 146982
BRN 1420457
Stability:Stable. Incompatible with strong oxidizing agents. Combustible.
InChIKeyRCINICONZNJXQF-MZXODVADSA-N
LogP3.950 (est)
CAS DataBase Reference33069-62-4(CAS DataBase Reference)
EPA Substance Registry SystemPaclitaxel (33069-62-4)

Safety Information

Hazard Codes Xn
Risk Statements 37/38-41-42/43-62-68-40-48-20/21/22-68/20/21/22
Safety Statements 22-26-36/37/39-45
RIDADR 1544
WGK Germany 3
RTECS DA8340700
F 45951
HazardClass 6.1(b)
PackingGroup III
HS Code 29329990
Hazardous Substances Data33069-62-4(Hazardous Substances Data)
ToxicityLD50 intraperitoneal in mouse: 128mg/kg

Paclitaxel CAS#33069-62-4

 

 

 

WhatsApp